Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Mucosal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Melanoma, Recurrent Uveal Melanoma, Small Size Posterior Uveal Melanoma, Stage IIA Cutaneous Melanoma AJCC v6 and v7, Stage IIA Uveal Melanoma AJCC v7, Stage IIB Cutaneous Melanoma AJCC v6 and v7, Stage IIB Uveal Melanoma AJCC v7, Stage IIC Cutaneous Melanoma AJCC v6 and v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions: Laboratory Biomarker Analysis, Placebo, Sargramostim, Tyrosinase Peptide; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 815 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 148
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 117 more

Conditions: Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions: Liposomal aerosol cyclosporine, standard immune suppression, oral; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: QGE031, Omalizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 22
States / cities: Fresno, California • Hawaiian Gardens, California • Riverside, California + 19 more

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Raynaud Phenomenon
Interventions: Botulinum toxin; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pain
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Migraine, Insomnia
Interventions: Stimulus Control and Sleep Restriction, Lifestyle Modification; Behavioral
Lead sponsor: Daniel Riche; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: University, Mississippi

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: placebo for SHAPE (SHP-141), SHAPE (SHP-141) 0.1% BID, SHAPE (SHP-141) 0.5% BID, SHAPE (SHP-141) 1.0% BID; Drug
Lead sponsor: TetraLogic Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Cleveland, Ohio + 2 more

Conditions: Multiple Myeloma
Interventions: Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT); Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Type 2 Diabetes
Interventions: Degludec, Glargine, Aspart; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions: Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more

Conditions: Episodic Migraine
Interventions: Xeomin, Placebo; Drug
Lead sponsor: Merz Therapeutics GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 47
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more

Conditions: Breast Cancer
Interventions: Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment; Drug · Procedure · Other + 1 more
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Gestational Diabetes, Endothelial Dysfunction, Physical Inactivity
Interventions: Insulin aspart; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Weight Gain
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Lymphoma
Interventions: Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more

Conditions: End Stage Renal Disease, Infection
Interventions: Intravenous antibiotics; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia
Interventions: PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more

Conditions: Myocarditis Acute, Cancer
Interventions: Abatacept plus, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 29
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more

Conditions: Psoriasis
Interventions: Risankizumab, Ustekinumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more

Conditions: Influenza, Influenza Immunisation
Interventions: Influenza Multimeric-001 Vaccine, Placebo, Quadrivalent Recombinant Seasonal Influenza Vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Houston, Texas

Conditions: Healthy
Interventions: Eggs; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Botulinum Toxin in Raynaud's Phenomenon

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

Efficacy of Behavioral Insomnia Treatment for Chronic Migraine

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

NATIENS: Optimal Management and Mechanisms of SJS/TEN

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Intradialytic Drug Removal by Short-daily Hemodialysis

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Abatacept in Immune Checkpoint Inhibitor Myocarditis

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

The Effect of Eggs on Postprandial Metabolism